# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PharmAust Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Roger Aston
Date of last notice	9 November 2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	31 October 2023
No. of securities held prior to change	15,044,815 Ordinary Fully Paid Shares 3,649,904 Listed Options 31/10/2023 – 20c
Class	Listed Options 31/10/2023 – 20c
Number acquired	Nil
Number disposed	3,649,904
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	
No. of securities held after change	15,044,815 Ordinary Fully Paid Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of options

<sup>+</sup> See chapter 19 for defined terms.

o1/o1/2011 Appendix 3Y Page 1

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Titular e of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 – \*Closed period

Were the interests in the securities or contracts detailed	No
above traded during a <sup>+</sup> closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	
to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

01/01/2011 Appendix 3Y Page 3

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PharmAust Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Robert Charles Bishop
Date of last notice	7 July 2023

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	The securities are held by Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited.
	Mr Bishop is the sole shareholder and director of Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited.
Date of change	31 October 2023
No. of securities held prior to change	9,511,060 Ordinary Fully Paid Shares 2,302,766 Listed Options 31/10/2023 – 20c 150,000 Unlisted Options 30/04/26 – 15c
Class	Listed Options 31/10/2023 – 20c
Number acquired	Nil
Number disposed	2,302,766
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	
No. of securities held after change	9,511,060 Ordinary Fully Paid Shares 150,000 Unlisted Options 30/04/26 – 15c
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Listed Options

<sup>+</sup> See chapter 19 for defined terms.

o1/o1/2011 Appendix 3Y Page 1

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Titular e of interess	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 – \*Closed period

No

01/01/2011 Appendix 3Y Page 3

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PharmAust Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Sam Michael Wright
Date of last notice	7 July 2023

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	The securities are held by Straight Lines Consultancy Pty Ltd as trustee for the Straight Lines Trust. Mr Wright is a Director of Straight Lines Consultancy Pty Ltd and a Beneficiary of the Straight Lines Trust.
Date of change	31 October 2023
No. of securities held prior to change	4,550,000 Ordinary Fully Paid Shares 875,000 Listed Options 31/10/2023 – 20c 250,000 Unlisted Options 30/04/26 – 15c
Class	Listed Options 31/10/2023 – 20c
Number acquired	Nil
Number disposed	875,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	
No. of securities held after change	4,550,000 Ordinary Fully Paid Shares 250,000 Unlisted Options 30/04/26 – 15c
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Listed Options

<sup>+</sup> See chapter 19 for defined terms.

o1/o1/2011 Appendix 3Y Page 1

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract			
Nature of interest			
Name of registered holder (if issued securities)			
Date of change			
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed			
Interest acquired			
Interest disposed			
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation			
Interest after change			
Part 3 – <sup>+</sup> Closed period			
Were the interests in the securities or co	ontracts detailed	No	
above traded during a <sup>+</sup> closed period where prior written clearance was required?			
If so, was prior written clearance provided to allow the trade to proceed during this period?			
If prior written clearance was provided, provided?	on what date was this		

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PharmAust Limited
ABN	35 094 006 023

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Neville Bassett
Date of last notice	7 July 2023

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
(including registered holder)	Shares are held by Mandevilla Pty Ltd. Mr Bassett is a director and shareholder of Mandevilla Pty Ltd.
Date of change	31 October 2023
No. of securities held prior to change	507,000 Ordinary Fully Paid Shares 1,750 Listed Options 31/10/2023 – 20c 250,000 Unlisted Options 30/04/26 – 15c
Class	Listed Options 31/10/2023 – 20c
Number acquired	Nil
Number disposed	1,750
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	
No. of securities held after change	507,000 Ordinary Fully Paid Shares 250,000 Unlisted Options 30/04/26 – 15c
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of Listed Options

<sup>+</sup> See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	
Part 3 – <sup>+</sup> Closed period	
Were the interests in the securities or contracts detailed	No
above traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this	

provided?

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.